secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001104659-26-033592
Event type: regulatory
Sentiment:  neutral
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute provides FDA meeting update after Phase 3 HI trial missed primary endpoint
--------------------------------------------------------------------------------

- sunRIZE Phase 3 ersodetug trial missed primary endpoint (SMBG hypoglycemia reduction); FDA acknowledged behavioral confounders.
- FDA encouraged submission of study reports and analysis datasets for independent evaluation; company expects update in H2 2026.
- Preliminary open-label extension data show continued glycemic improvement and reduction of background therapies.
- Company believes FDA did not dismiss program; outcomes to be presented at upcoming scientific conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926033592/0001104659-26-033592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926033592/tm269642d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-033592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer